RATIONALE-309

Background

Phase III double-blind RCT (RATIONALE-309). N=263 patients with R/M NPC (first-line), ECOG PS 0–1, no prior systemic chemotherapy for R/M disease. Enrolled 2019–2020 at 41 global sites (predominantly China). Tislelizumab is a humanized anti-PD-1 antibody with minimal Fc effector function. Stratified by liver metastasis, ECOG PS, and number of metastatic sites.

Interventions and follow up

Arm A: Tislelizumab 200 mg D1 q3wk + gemcitabine 1000 mg/m² D1,D8 + cisplatin 75 mg/m² D1 q3wk × 6 cycles → tislelizumab maintenance
Arm B: Placebo + gemcitabine + cisplatin × 6 cycles → placebo maintenance
Primary endpoint: PFS (investigator)
mFollow up: 15.5 months (primary analysis)

Results

mPFS: Not reached (tislelizumab) vs 7.4 months (placebo), HR 0.52 (95% CI 0.38–0.73), P<.0001
1-year PFS: 57.0% vs 24.6%
ORR: 80.0% vs 71.6%
OS: Immature at primary analysis; HR 0.51 in exploratory analysis

Adverse events

Main adverse events: Grade ≥3 AEs: 89.0% (tislelizumab) vs 86.3% (placebo). Most grade 3–4 events were chemotherapy-related: anemia, neutropenia, thrombocytopenia. Immune-related grade ≥3: 5.8% vs 0.8%. No significant excess immune toxicity vs placebo arm.

Conclusions

Tislelizumab + gemcitabine-cisplatin significantly improved PFS (HR 0.52) with 1-year PFS of 57% vs 25% vs placebo + GP in first-line R/M NPC. Results are consistent with CAPTAIN-1st and JUPITER-02, collectively establishing PD-1 inhibition + GP as the first-line standard for R/M NPC.

Key Limitations

Key Limitations: Primary analysis based on relatively short median follow-up (15.5 months) — PFS was primary, OS immature. Conducted predominantly in endemic NPC — generalizability limited. All three positive IO trials (CAPTAIN-1st, RATIONALE-309, JUPITER-02) enrolled nearly exclusively Asian patients with EBV-positive NPC. No biomarker selection; PD-L1 testing not required. Tislelizumab is approved in China and select markets but not yet globally available.

Clinical Context

RATIONALE-309 (BeiGene/Novartis) supports tislelizumab + GP as a first-line option for R/M NPC. The 3-year update (Yang Y et al, JAMA Oncol 2026) confirmed durable OS benefit (HR 0.52). Together with CAPTAIN-1st and JUPITER-02, three positive phase III trials establish PD-1 + GP as category 1 first-line treatment for R/M NPC across NCCN and ESMO guidelines. In the US, pembrolizumab-based data have more regulatory traction; global approvals for tislelizumab are ongoing.

References

References: Yang Y et al, Cancer Cell 2023 (primary)